Seaside Wellness
  • Sign In
  • Create Account
  • Bookings
  • My Account

  • Signed in as:

  • filler@godaddy.com

  • Bookings
  • My Account

  • Sign out

  • Home
  • About Us
  • Patient Information
  • Success Stories
  • FAQ
  • Clinical Studies
  • Contact Us
  • More
    • Home
    • About Us
    • Patient Information
    • Success Stories
    • FAQ
    • Clinical Studies
    • Contact Us
Seaside Wellness

Signed in as:

filler@godaddy.com

  • Home
  • About Us
  • Patient Information
  • Success Stories
  • FAQ
  • Clinical Studies
  • Contact Us

Account

  • Bookings
  • My Account

  • Sign out

  • Sign In
  • Bookings
  • My Account

Tirzepatide Tops TRT for Men With Hypogonadism and Obesity

Short-term impact of tirzepatide on metabolic hypogonadism and body composition in patients with obe

Short-term impact of tirzepatide on metabolic hypogonadism and body composition in patients with obe

In a study of 83 men with obesity, functional hypogonadism, and insulin resistance, those treated with the dual glucose-dependent insulinotropic peptide and glucagon-like peptide 1 (GLP-1) receptor agonist tirzepatide for 2 months had greater weight loss, increased endogenous testosterone production, and improved erectile dysfunction compared to those treated with transdermal testosterone replacement therapy (TRT) or who received no treatment. 

Short-term impact of tirzepatide on metabolic hypogonadism and body composition in patients with obe

Short-term impact of tirzepatide on metabolic hypogonadism and body composition in patients with obe

Short-term impact of tirzepatide on metabolic hypogonadism and body composition in patients with obe

Tirzepatide (TZP), a dual agonist of glucose-dependent insulinotropic peptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors, has recently been introduced in Italy for the treatment of obesity. Obesity is frequently associated with metabolic hypogonadism, which is characterized by low testosterone levels and normal low levels of gonadotropin. This condition exacerbates metabolic dysfunction and increases the risk of type 2 diabetes mellitus (DM). This study aims to evaluate the effects of TZP on metabolic hypogonadism in patients with obesity.

A New Use for Wegovy Opens the Door to Medicare Coverage for Millions of People with Obesity

A New Use for Wegovy Opens the Door to Medicare Coverage for Millions of People with Obesity

A New Use for Wegovy Opens the Door to Medicare Coverage for Millions of People with Obesity

FDA approval of Wegovy to lower stroke, heart attack risk makes around 3.6M Medicare patients with overweight, obesity eligible for coverage, study finds

Clinical Insight on Semaglutide for Chronic Weight Management in Adults

A New Use for Wegovy Opens the Door to Medicare Coverage for Millions of People with Obesity

A New Use for Wegovy Opens the Door to Medicare Coverage for Millions of People with Obesity

The novel anti-obesity medication semaglutide 2.4 mg injected subcutaneously once weekly as an adjunct to a reduced-calorie diet and physical activity helps patients achieve average losses of 9.6–17.4% of initial body weight at week 68, as well as improvements in cardiometabolic and psychosocial indices. 

Do Patients on Anti-Obesity Drugs Decrease Alcohol Use?

A New Use for Wegovy Opens the Door to Medicare Coverage for Millions of People with Obesity

Do Patients on Anti-Obesity Drugs Decrease Alcohol Use?

Several types of anti-obesity medications (AOMs), including glucagon-like peptide 1s (GLP-1s), are associated with decreased alcohol use, new research suggests.

Glycine: The Smallest Anti-Inflammatory Micronutrient

Do Patients on Anti-Obesity Drugs Decrease Alcohol Use?

In this review, we emphasize that glycine exerts its anti-inflammatory effects throughout the modulation of the expression of nuclear factor kappa B (NF-κB) in many cells. Although glycine is a non-essential amino acid, we highlight how dietary glycine supplementation is important in avoiding the development of chronic inflammation.

The Growing Scientific Case for Using Ozempic and other GLP-1s to Treat Opioid, Alcohol, and Nicotin

Evidence that GLP-1 treatments like Ozempic and Mounjaro have strong anti-addictive effects across substances and behaviors has been mounting every month.

Semaglutide Eligibility Across All Current Indications for US Adults

Rapidly increasing uptake of semaglutide made it the top-selling drug in the US in 2023, with net sales of $13.8 billion.1,2 Quantifying the number of US adults eligible for semaglutide may guide future policies for this high-cost therapy and clarify potential implications for pharmaceutical spending.

Efficacy and Safety of Glucagon-Like Peptide-1 Receptor

Glucagon-Like Peptide 1 Receptor Agonists and Risk of Thyroid Cancer: An International Multisite Coh

Glucagon-Like Peptide 1 Receptor Agonists and Risk of Thyroid Cancer: An International Multisite Coh

Recent randomized controlled trials (RCTs) have investigated glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and dual or triple co-agonists for weight loss among adults with overweight or obesity and without diabetes.

Glucagon-Like Peptide 1 Receptor Agonists and Risk of Thyroid Cancer: An International Multisite Coh

Glucagon-Like Peptide 1 Receptor Agonists and Risk of Thyroid Cancer: An International Multisite Coh

Glucagon-Like Peptide 1 Receptor Agonists and Risk of Thyroid Cancer: An International Multisite Coh

 Concerns have been raised that glucagon-like peptide 1 receptor agonists (GLP1-RAs) may increase the risk of thyroid cancer, but evidence remains conflicting. We therefore investigated if GLP1-RA use, compared with use of dipeptidyl peptidase-4 inhibitors (DPP-4is), was associated with thyroid cancer risk in patients with type 2 diabetes.

Early Intervention Central to Treating Muscle Mass Loss in Patients Losing Weight With GLP-1 Meds

Glucagon-Like Peptide 1 Receptor Agonists and Risk of Thyroid Cancer: An International Multisite Coh

Early Intervention Central to Treating Muscle Mass Loss in Patients Losing Weight With GLP-1 Meds

With glucagon-like peptide 1 (GLP-1) agonists now close to inducing weight loss at levels only seen before through surgical intervention, obesity specialists say patients on these drugs are experiencing complications similar to those seen after weight loss surgery.

GLP-1s Show No Increased Risk for Thyroid Cancer

Body composition changes during weight reduction with tirzepatide

Early Intervention Central to Treating Muscle Mass Loss in Patients Losing Weight With GLP-1 Meds

“While we cannot rule out [developments] 20 years from now, we can say that we do not see the same short-term association that others have reported,” senior author Anton Pottegard, PhD, of Clinical Pharmacology, Pharmacy and Environmental Medicine, Department of Public Health, University of Southern Denmark, Odense, told Medscape Medical News.

Once-Weekly Semaglutide in Adults With Alcohol Use Disorder

Body composition changes during weight reduction with tirzepatide

Body composition changes during weight reduction with tirzepatide

In this randomized clinical trial, relative to placebo, low-dose semaglutide reduced the amount of alcohol consumed during a posttreatment laboratory self-administration procedure. Over 9 weeks of treatment, semaglutide led to reductions in some but not all measures of weekly consumption, significantly reduced weekly alcohol craving relative to placebo, and led to greater relative reductions in cigarettes per day in a subgroup of participants with current cigarette use.

Body composition changes during weight reduction with tirzepatide

Body composition changes during weight reduction with tirzepatide

Body composition changes during weight reduction with tirzepatide

We assessed changes in body composition following tirzepatide treatment in a substudy of participants with obesity or overweight from the SURMOUNT-1 trial, overall and post hoc in clinically relevant subgroups.

Seaside Wellness

admin@seasidewellnessllc.com

302-360-8207 (p) 260-234-3441 (f)

Copyright © 2025 Seaside Wellness - All Rights Reserved.


Terms & Conditions    Privacy Policy 


This website uses cookies.

We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.

Accept